Testing Upadacitinib for immune disorders caused by gene changes
Treatments studied
Part of Immune system & allergy clinical trials.
This trial tests the drug upadacitinib for people with overactive immune systems due to a specific genetic mutation in the JAK/STAT pathway. The goal is to see if the drug can help control symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must weigh at least 30 kg (about 66 pounds).
- You must have a confirmed genetic change in the JAK/STAT pathway that makes your immune system overactive.
- Your current illness must meet specific scoring criteria set by the study doctors.
- You need to be expected to live longer than 12 months.
- You must agree to let researchers store your blood or tissue samples for future studies.
- If you can become pregnant, you must commit to using very effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medication called upadacitinib for people with inflammatory bowel disease (ulcerative colitis or Crohn's). The goal is to see how well it works and if it's safe.
This trial tests if a higher dose of upadacitinib can help people with ulcerative colitis who stopped responding to the 30 mg daily dose. It aims to see if re-inducing with a stronger dose can bring back symptom control.
This trial provides early access to a medication called upadacitinib for people who have no other suitable treatment options and cannot join a clinical trial. Upadacitinib may help manage certain conditions when standard treatments have not worked.
This trial tests whether the drug upadacitinib can help people with giant cell arteritis (GCA) that affects the large blood vessels, such as the aorta. It is for those who have not responded to, cannot tolerate, or cannot use another treatment called tocilizumab.
This study tests an oral tablet called upadacitinib for people with severe alopecia areata who have lost at least half of their scalp hair. It aims to see if the drug can safely help hair regrow.
This Phase 3 trial studies how well upadacitinib (a pill) and tocilizumab (a shot/IV medicine) improve symptoms and inflammation in children with active systemic juvenile idiopathic arthritis (sJIA). It also looks at side effects and how these medicines move through the body.
Hear when a new JAK1 GOF trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.